文献速递药物相互作用肝肾功能剂量调整

阿地那非与克拉霉素、西咪替丁或利福平在健康受试者中的药代动力学与安全性相互作用

Pharmacokinetic and safety interactions between aildenafil and clarithromycin, cimetidine, or rifampin in healthy subjects.
PubMed 文献 · Br J Clin Pharmacol · 2026-09-13

本研究在健康受试者中开展三项开放标签、固定序列试验,评估阿地那非60mg单次给药与克拉霉素(CYP3A4抑制剂)、利福平(诱导剂)或西咪替丁联用的药代动力学相互作用。结果显示克拉霉素显著增加阿地那非暴露(AUC0-∞几何均值比2.58),利福平显著降低其暴露(AUC0-∞几何均值比0.01),西咪替丁无显著影响。

要点

  • 克拉霉素使阿地那非AUC0-∞增加2.58倍、Cmax增加1.67倍,需根据临床反应和耐受性调整剂量。
  • 利福平使阿地那非AUC0-∞降至0.01倍、Cmax降至0.02倍,不推荐联合使用。
  • 西咪替丁对阿地那非暴露无显著影响(AUC0-∞几何均值比1.17)。

核心结论

  • 克拉霉素显著增加阿地那非暴露,剂量调整应依据临床反应和耐受性。
  • 利福平显著降低阿地那非血清浓度,不推荐联合给药。
  • 西咪替丁对阿地那非暴露无显著影响。

研究设计与样本

  • 三项开放标签、固定序列试验,在健康受试者中进行。
  • 受试者单次口服阿地那非60 mg,并与克拉霉素(500 mg,N=18)、利福平(600 mg,N=18)或西咪替丁(400 mg,N=18)多次给药联合。
  • 采用非房室分析计算药代动力学参数,全程监测不良事件。

主要发现

  • 克拉霉素使阿地那非Cmax几何均值比(90% CI)为1.67(1.51-1.85),AUC0-∞为2.58(2.42-2.76)。
  • 利福平使阿地那非Cmax几何均值比(90% CI)为0.02(0.02-0.03),AUC0-∞为0.01(0.01-0.02)。
  • 西咪替丁使Cmax和AUC0-∞的几何均值比(90% CI)分别为0.99(0.84-1.16)和1.17(1.10-1.25)。

关键数值与推荐

  • 克拉霉素(CYP3A4抑制剂)与阿地那非联用时,AUC0-∞增加2.58倍,Cmax增加1.67倍。
  • 利福平(CYP3A4诱导剂)与阿地那非联用时,AUC0-∞降至0.01倍,Cmax降至0.02倍。
  • 西咪替丁与阿地那非联用时,AUC0-∞几何均值比1.17(90% CI 1.10-1.25),Cmax几何均值比0.99(90% CI 0.84-1.16)。

临床怎么用

  • 与克拉霉素联用时,应根据临床反应和耐受性调整阿地那非剂量。
  • 避免阿地那非与利福平联合使用。
  • 与西咪替丁联用无需调整阿地那非剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Aildenafil citrate, an orally bioavailable phosphodiesterase type 5 (PDE5) inhibitor, is primarily metabolized by cytochrome P450 3A4 (CYP3A4). This study aimed to assess potential pharmacokinetic interactions between aildenafil citrate tablets and cytochrome P450 (CYP)3A modulators. METHODS: This study involved three open-label, fixed-sequence trials in healthy subjects. Participants received a single oral dose of aildenafil 60 mg alone and with repeated doses of clarithromycin (500 mg, CYP3A4 inhibitor, N = 18), rifampin (600 mg, inducer, N = 18), or cimetidine (400 mg, N = 18). Pharmacokinetic (PK) parameters-including maximum serum concentration (Cₘₐₓ), area under the concentration-time curve (AUC), time to reach Cₘₐₓ, and half-life (t1/2)-were calculated using noncompartmental analysis from serial serum aildenafil concentrations. Adverse events were monitored throughout. RESULTS: Clarithromycin significantly increased aildenafil exposure, with geometric mean ratios (90% CI) of 1.67 (1.51-1.85) for Cmax and 2.58 (2.42-2.76) for AUC0-∞. Conversely, rifampin markedly reduced aildenafil serum concentrations, with geometric mean ratios (90% CI) of 0.02 (0.02-0.03) for Cmax and 0.01 (0.01-0.02) for AUC0-∞. Coadministration with cimetidine resulted in log-transformed Cmax and AUC0-∞ ratios near 1.0 (0.99 and 1.17, respectively), with geometric mean ratios (90% CI) of 0.99 (0.84-1.16) and 1.17 (1.10-1.25), indicating no significant effect on aildenafil exposure. CONCLUSIONS: Coadministration of aildenafil with the strong CYP3A4 inhibitor clarithromycin increased aildenafil AUC0-∞ by 2.58-fold and Cmax by 1.67-fold; therefore, dose adjustment should be guided by clinical response and tolerability. In contrast, coadministration with the strong CYP3A4 inducer rifampin is not recommended.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Xie R, Zhao N, Jia B, et al. Pharmacokinetic and safety interactions between aildenafil and clarithromycin, cimetidine, or rifampin in healthy subjects. Br J Clin Pharmacol. 2026. PMID: 42732925. doi:10.1002/bcp.70781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。